Ceftazidime-Avibactam Market Revenue to Attain USD 6.62 Bn by 2033

22 Aug 2025

Share :

Table of Content

1. Ceftazidime-Avibactam Market Revenue and Trends 2025 to 2033 2. Key drivers enabling the growth of the Ceftazidime-Avibactam Market 3. Segment Insights 4. Regional Insights 5. Ceftazidime-Avibactam Market Coverage 6. Ceftazidime-Avibactam Market Key Players

Ceftazidime-Avibactam Market Revenue and Trends 2025 to 2033

The global ceftazidime-avibactam market revenue was valued at USD 3.56 billion in 2025 and is expected to attain around USD 6.62 billion by 2033, growing at a CAGR of 8.05% during forecast period. This market is rising due to the growing prevalence of multidrug-resistant bacterial infections and the urgent global demand for effective next-generation antibiotic therapies.

Key drivers enabling the growth of the Ceftazidime-Avibactam Market

The ceftazidime-avibactam market is largely driven by the increasing prevalence of multidrug resistant (MDR) bacterial infections, particularly with carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa, creating an urgent need for new treatment options in this space. Increasing hospital-acquired infections and the growing population of immunocompromised patients serve to further bolster market utilization. Increasing regulatory supply and robust R&D pipeline activity in novel combination therapies, also continues to drive the market.

Additional support from increased awareness among healthcare practitioners about antibiotic stewardship and ceftazidime-avibactam being recognized as a suggested therapy option, all reinforce its use clinically. Furthermore, expansion into emerging markets that have severe cases of the antimicrobial resistance crisis, alongside government support that is linked to increasing innovative antimicrobial solutions and promoted and funded initiatives, continues to bolster the global outlook for the ceftazidime-avibactam markets.

Segment Insights

• By formulation, the market is led by an IV injection segment. IV injection is preferred in cases requiring rapid drug delivery, superior bioavailability, and hospitals' preference for the management of severe infections.
• By indication, the complicated urinary tract infections (cUTIs) segment is dominating the market at the forefront due to increasing rates of infection and the drug's clinical efficacy in overcoming multidrug-resistant pathogens.
• By end-user, in the ceftazidime-avibactam market, the hospital segment is dominant due to high patient admission volumes, a critical need to manage infections, and increasing demand for effective treatment against resistant bacterial infections.
• By distribution channel, in this market, the hospital pharmacy segment leads primarily due to access to drugs in an emergency, increased in-patient treatment, and a reliance on hospital-based distribution of essential antibiotics.

Regional Insights

The ceftazidime-avibactam market has a dominant position in North America owing to extremely high rates of multidrug-resistant bacterial infections, strong healthcare infrastructure in the region, high regulatory support/engagement, favorable reimbursement and easy access to advanced diagnostics and tools to support rapid uptake of new antibiotics. If that were not enough, the growing incidence of hospital-acquired infections, and rise in immunocompromised patients providing clinical demand. It also supports co-development and co-design models with partners in research and pharmaceutical development across the USA and Canada.

The Asia-pacific marketplace for ceftazidime-avibactam represents a rapidly growing opportunity because of the alarming rates of multiple-drug resistance and hospital admission rates across the region. With additional healthcare infrastructure grounded in large patients’ cohorts imply adoption of new antibiotics including advanced antibiotics is growing across China, India, Japan and other regional countries. Government initiatives to treat use of antibiotic agents to limit antimicrobial resistance, along with increased investment in management of infectious disease as part of health issues further drives demand. In addition, there continues to be a growing emphasis by global pharmaceutical companies to invest in growing real estate in the Asia-Pacific to support access to advanced antibiotics from ceftazidime-avibactam and market adoption.

Ceftazidime-Avibactam Market Coverage

Recent Developments

• On January 30, 2023, Alkem introduced its domestically produced ceftazidime-avibactam combination under the brand name Zidavi, aimed at treating multidrug-resistant (MDR) infections—including OXA-48-like and KPC-producing CRE. They emphasized affordability, accessibility, and alignment with IDSA and ICMR guidelines. (Source: https://health.economictimes.indiatimes.com)

Ceftazidime-Avibactam Market Key Players

• Pfizer Inc.
• Allergan plc
• Cipla Limited
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories
• Sandoz International GmbH
• Hikma Pharmaceuticals
• Aurobindo Pharma Ltd.
• Lupin Limited
• Teva Pharmaceutical Industries Ltd.
• Fresenius Kabi AG
• Mylan N.V.
• Zydus Cadila
• Torrent Pharmaceuticals Ltd.
• Amneal Pharmaceuticals
• Hetero Drugs Ltd.
• Glenmark Pharmaceuticals
• Natco Pharma Ltd.
• Jubilant Life Sciences
• Alembic Pharmaceuticals

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6623

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344